Abstract
Recombinant interleukin-2 is used with ch14.18/CHO to improve the cytotoxic activity of NK lymphocytes against neoplastic cells. The efficacy of this treatment is limited by its potential side effects. We report an unusual case of necrotizing enterocolitis associated with the administration of interleukin-2 and ch14.18/CHO in maintenance therapy for localized NMyc amplified neuroblastoma (NBL). This case highlights the potentially significant toxicity of this immunotherapy that is currently being tested in the high-risk NBL-1.5 protocol. Further, short-term, medium-term, and long-term follow-up in this patient population will be warranted to judge the potential benefit of this treatment versus the short-term, medium-term, and long-term side effects in a patient population with an outcome that is better than that of stage 4 NBL patients.
References
Aug 1, 1992·Journal of Immunotherapy·E WeidmannP S Mitrou
Jan 11, 1992·Cancer·D S WadeH O Douglass
Dec 19, 2000·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·M F OzkaynakR C Seeger
Nov 22, 2001·AJR. American Journal of Roentgenology·W WiesnerP R Ros
Apr 13, 2004·Journal of Immunotherapy·David M Heimann, Douglas J Schwartzentruber
Aug 4, 2007·The Oncologist·Jeffrey Weber
Dec 3, 2008·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Andrew L GilmanPaul M Sondel
Jan 28, 2009·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Katherine K MatthayJudith G Villablanca
Aug 25, 2009·Strahlentherapie und Onkologie : Organ der Deutschen Röntgengesellschaft ... [et al]·Tobias BöllingNormann Willich
Dec 25, 2009·Pediatric Nephrology : Journal of the International Pediatric Nephrology Association·Agnieszka PrytułaKjell Tullus
Jun 23, 2010·Pediatrics·Daniela S ArdeleanSusanne M Benseler
Oct 1, 2010·The New England Journal of Medicine·Alice L YuUNKNOWN Children's Oncology Group
Dec 15, 2010·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Ruth LadensteinJean Michon
Aug 9, 2013·MAbs·Ruth LadensteinHolger N Lode
Citations
Nov 16, 2018·Expert Opinion on Drug Safety·Katie L Greenwood, Jennifer H Foster
May 17, 2019·Immunotherapy·Parnian JabbariNima Rezaei
Jan 12, 2020·Pediatric Blood & Cancer·Katherine SpencerNavin Pinto
Mar 9, 2021·Frontiers in Oncology·Thomas BlomGodelieve Tytgat
May 20, 2021·International Journal of Nanomedicine·Liyu ZhangHui Li